CA3252689A1 - AQUEOUS SOLUTION OF TICAGRELOR, MANUFACTURING PROCESS AND USES - Google Patents
AQUEOUS SOLUTION OF TICAGRELOR, MANUFACTURING PROCESS AND USESInfo
- Publication number
- CA3252689A1 CA3252689A1 CA3252689A CA3252689A CA3252689A1 CA 3252689 A1 CA3252689 A1 CA 3252689A1 CA 3252689 A CA3252689 A CA 3252689A CA 3252689 A CA3252689 A CA 3252689A CA 3252689 A1 CA3252689 A1 CA 3252689A1
- Authority
- CA
- Canada
- Prior art keywords
- ticagrelor
- aqueous
- solution
- cyclodextrin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2022/063185 WO2023222184A1 (en) | 2022-05-16 | 2022-05-16 | Aqueous ticagrelor solution, method of manufacturing and uses |
| EPPCT/EP2022/063185 | 2022-05-16 | ||
| EPPCT/EP2023/055736 | 2023-03-07 | ||
| EP2023055736 | 2023-03-07 | ||
| PCT/EP2023/063071 WO2023222660A1 (en) | 2022-05-16 | 2023-05-16 | Aqueous ticagrelor solutions, method of manufacturing and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3252689A1 true CA3252689A1 (en) | 2023-11-23 |
Family
ID=86604209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3252689A Pending CA3252689A1 (en) | 2022-05-16 | 2023-05-16 | AQUEOUS SOLUTION OF TICAGRELOR, MANUFACTURING PROCESS AND USES |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235455A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4525931A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025515559A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250024925A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119212736A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023271339A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3252689A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024013807A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023222660A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260113060A (ko) * | 2023-11-16 | 2026-07-21 | 하이로리스 디벨롭먼츠 에스에이 | 피부경유 관상동맥 중재술 (pci)을 겪은 환자에서 허혈성 사건의 치료, 감소 또는 예방에 사용을 위한 티카그렐러 iv |
| WO2025104274A1 (en) * | 2023-11-16 | 2025-05-22 | Hyloris Developments Sa | Ticagrelor iv for use in the prevention of thromboembolic events |
| AU2024386725A1 (en) * | 2023-11-22 | 2026-04-30 | Hyloris Developments Sa | Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake |
| CN117919246A (zh) * | 2024-01-26 | 2024-04-26 | 重庆东得医药科技有限公司 | 一种以左西孟旦为活性成分的组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3100728T3 (pl) * | 2009-05-13 | 2020-05-18 | Cydex Pharmaceuticals, Inc. | Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania |
| CN110917167A (zh) * | 2018-09-19 | 2020-03-27 | 河南天晟泰丰医药科技有限公司 | 替格瑞洛肠溶缓释软胶囊及其制备方法 |
| WO2021096444A1 (en) * | 2019-11-13 | 2021-05-20 | Santa Farma İlaç Sanayi̇ A.Ş. | Pharmaceutical compositions comprising ticagrelor |
-
2023
- 2023-05-16 US US18/855,499 patent/US20250235455A1/en active Pending
- 2023-05-16 EP EP23726507.9A patent/EP4525931A1/en active Pending
- 2023-05-16 JP JP2024557894A patent/JP2025515559A/ja active Pending
- 2023-05-16 CN CN202380040644.0A patent/CN119212736A/zh active Pending
- 2023-05-16 KR KR1020247041152A patent/KR20250024925A/ko active Pending
- 2023-05-16 WO PCT/EP2023/063071 patent/WO2023222660A1/en not_active Ceased
- 2023-05-16 AU AU2023271339A patent/AU2023271339A1/en active Pending
- 2023-05-16 CA CA3252689A patent/CA3252689A1/en active Pending
-
2024
- 2024-11-07 MX MX2024013807A patent/MX2024013807A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119212736A (zh) | 2024-12-27 |
| US20250235455A1 (en) | 2025-07-24 |
| EP4525931A1 (en) | 2025-03-26 |
| JP2025515559A (ja) | 2025-05-20 |
| WO2023222660A1 (en) | 2023-11-23 |
| KR20250024925A (ko) | 2025-02-20 |
| MX2024013807A (es) | 2025-02-10 |
| AU2023271339A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250235455A1 (en) | Aqueous ticagrelor solutions, method of manufacturing and uses | |
| US12383622B2 (en) | Pre-mixed, ready-to-use pharmaceutical compositions | |
| WO2023222184A1 (en) | Aqueous ticagrelor solution, method of manufacturing and uses | |
| CN103002877A (zh) | 作为缓解疾病的抗风湿性药(dmard)和抗癌药剂的甲氨蝶呤的持续释放制剂 | |
| WO2025104277A1 (en) | Ticagrelor iv for use in the treatment, reduction or prevention of an ischemic event in a patient undergoing a percutaneous coronary intervention (pci) | |
| WO2022091122A1 (en) | Stable remdesivir formulations | |
| WO2025104274A1 (en) | Ticagrelor iv for use in the prevention of thromboembolic events | |
| WO2024188947A1 (en) | Ticagrelor iv formulations for use in the treatment of gram-positive bacteremia | |
| WO2025108980A1 (en) | Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake | |
| JP6033931B2 (ja) | 有機溶媒無含有ゲムシタビン水溶液組成物 | |
| US20250114342A1 (en) | Apixaban oral liquid dosage forms | |
| EP4382093A1 (en) | Oral suspensions comprising capecitabine | |
| TW202428273A (zh) | 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物 | |
| WO2011009956A1 (en) | Injectable aqueous solution containing artesunate | |
| WO2025051399A1 (en) | Liquid ticagrelor formulation | |
| JP2015000869A (ja) | 有機溶媒無含有ゲムシタビン水溶液組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241107 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250203 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250203 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250505 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250505 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260504 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260504 |